CXL treats radial keratotomy in the short-term

Article

Patients with radial keratotomy (RK) can be successfully treated with corneal cross-linking (CXL).

According to new results published in the journal Cornea patients with radial keratotomy (RK) can be successfully treated with corneal cross-linking (CXL).

The short-term case series, conducted by Dr Graciana Fuentes-Páez et al., Clinica Tacir-Centro Medico Teknon, Barcelona, Spain, featured seven eyes of four RK patients who underwent CXL with riboflavin and UV-A radiation.

Sphere, spherical equivalent (SE), uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), topographic astigmatism, mean topographic K (Km), pachymetry and Q values were all recorded 3 and 6 months after CXL.

After three months the findings revealed that the mean sphere of the patients was +1.0 ± 3.0 D, the astigmatism was 2.5 ± 1.2 D, SE was 0.3 ± 2.2 D and UCVA 0.41 ± 2.7. Additional findings showed that mean BSCVA was 0.80 ± 0.27, Km was 37.5 ± 5.7 D, pachymetry was 491 ± 33.74 μm and Q values were 2.27 ± 1.8.

Six months after CXL the findings improved further. Mean sphere was 0.53 ± 3.5 D, astigmatism was 1.62 ± 1.76 D, SE was 0.52 ± 2.9 D, UCVA was0.60 ± 2.0, BSCVA was 0.9 ± 0.15, Km was 38.3 ± 4.10 D, and Q values were 1.7 ± 0.78.

The data demonstrated a statistical and clinical significance in all areas on RK patients who underwent CXL.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.